TABLE 3.
Characteristic | ATI (U/mL)
|
P | |
---|---|---|---|
<5 (n = 107) | ≥5 (n = 27) | ||
Most recent diagnosis | |||
CD | 91 (85%) | 23 (85%) | 1.00 |
UC | 16 (15%) | 4 (15%) | |
Most recent disease severity | |||
CD (PCDAI) | 5.0 (0.0–10.0) | 0.0 (0.0–10.0) | 0.57 |
UC (PUCAI) | 10.0 (0.0–15.0) | 2.5 (0.0–15.0) | 0.53 |
Disease remission | |||
CD (PCDAI 0–10) | 76 (84%) | 19 (83%) | 1.00 |
UC (PUCAI 0–9) | 7 (44%) | 3 (75%) | 0.58 |
Months on infliximab | 27.6 (14.2–57.2)a | 19.2 (8.4–30.3) | 0.01 |
Combination therapy | 42 (39%) | 8 (30%) | 0.36 |
CRP obtained | 105 (98%) | 27 (100%) | 1.00 |
CRP | 0.10 (0.10–0.23) | 0.11 (0.10–0.46) | 0.34 |
CRP >0.5 | 11 (10%) | 5 (19%) | 0.32 |
Before discontinuation.